(NASDAQ: ANGO) Angiodynamics's forecast annual revenue growth rate of 4.56% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 9.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.95%.
Angiodynamics's revenue in 2026 is $313,725,000.On average, 6 Wall Street analysts forecast ANGO's revenue for 2027 to be $13,891,006,034, with the lowest ANGO revenue forecast at $13,257,173,878, and the highest ANGO revenue forecast at $14,360,388,908. On average, 5 Wall Street analysts forecast ANGO's revenue for 2028 to be $14,686,395,148, with the lowest ANGO revenue forecast at $14,055,042,126, and the highest ANGO revenue forecast at $15,228,086,123.
In 2029, ANGO is forecast to generate $15,506,575,610 in revenue, with the lowest revenue forecast at $14,733,498,711 and the highest revenue forecast at $16,139,168,199.